Apnimed to present pooled Phase 3 AD109 obstructive sleep apnea data at ATS 2026

  • Apnimed flagged new pooled Phase 3 analyses of its oral obstructive sleep apnea drug candidate AD109 for presentation at ATS 2026 in Orlando on May 17-20.
  • Data will be presented in three oral sessions, supported by a late-breaking poster, covering combined results from SynAIRgy and LunAIRo studies.
  • Company plans to highlight treatment-related improvements in obstructive sleep apnea, including reduced snoring.
  • Separate analysis is set to outline an estimated reduction in cardiovascular risk tied to improvements in oxygen-related disease burden on therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apnimed Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.